## South Asia Update

## Comprehensive update on cancer scenario of Bangladesh

#### Syed Md Akram Hussain

#### **Abstract**

Bangladesh, at 142 million people, is the ninth most populous country in the world. There are 13 to 15 lakh cancer patients in Bangladesh, with about two lakh patients newly diagnosed with cancer each year. As an overview, lung cancer and mouth-oropharynx cancer rank as the top two prevalent cancers in males. Other types of cancers are esophagus cancer and stomach cancer. In women, cancer cervix uteri and breast cancer are most prevalent. Other cancer types, which affect women, are mouth and oropharynx cancer, lung cancer, and esophagus cancer. There are around 150 qualified clinical oncologists and 16 pediatric oncologists working in the different parts of the country. Regular cancer treatment is available in 19 hospitals and 465 hospital beds are attached as indoor or day care facilities for chemotherapy in the oncology/radiotherapy departments. There are about 15 linear accelerators, 12 Co-60 teletherapy and 12 brachytherapy units currently available. Approximately, 56 cancer chemotherapeutic agents are obtainable in Bangladesh. Research facilities are available at tertiary care centers and a few multi country collaborative research activities are ongoing. Bangladesh has a unique National Cancer Control Strategy and Plan of Action 2009-2015 formulated with the assistance of WHO with an objective to develop and implement continuum of cancer care through a comprehensive cancer control programe. Preventive measures taken to reduce the incidence of cancer include reduced tobacco smoking, change of dietary habit and reduced food adulteration, ensuring reproductive hygiene, increased physical activity, and reduced occupational hazard. Awareness buildup and media campaign are going on by organizing the general people, opinion leaders of the society, and boy and girl scout. Training of general physicians on cancer warning signs and setup of early cancer detection centers at each medical college and district levels are ongoing. Beside these, some other major cancer programs have taken place for early detection of breast, cervical and oral cancer by Bangladesh Government and NGOs such as ICDDR'B, BRAC, Ahsania Mission Cancer Hospital, BSMMU, Bangladesh Cancer Society, Ashic Foundation, Amader Gram, AK Khan Healthcare Trust, CANSUP, Oncology club etc. Piloting of cervical cancer vaccination has recently been completed. Improving the cancer scenario overnight is not an easy task but policy makers may become interested and push this agenda forward, if the huge health impact and economic loss caused by cancer become evident to them. Besides, Bangladesh has accepted reduction of cancer morbidity and mortality targets set by United Nations and World Health Organization as a part of global non-communicable disease prevention agreement.

Key words: Cancer, prevalence, facilities, prevention, cancer programme, agency, Bangladesh

## Basic information on the oncology scenario, including the leading cancers, their prevalence, citing the causes of increased prevalence

Bangladesh, at 142 million people, is the 9<sup>th</sup> most populous country in the world. There are 13 to 15 lakh cancer patients in Bangladesh, with about 2 lakh patients newly diagnosed with cancer each year.<sup>[1,2]</sup>

As an overview, lung cancer and mouth and oropharynx cancer rank as the top 2 prevalent cancers in males. Other types of cancers commonly noted include esophagus cancer, stomach cancer, lymphomas, and multiple myeloma. In women, cervix

Department of Oncology, Khwaja Yunus Ali Medical College Cancer Center, Sirajgonj, Bangladesh

Correspondence to: Prof. Syed Md Akram Hussain,

E-mail: syedmdakram@gmail.com

Access this article online				
Quick Response Code:	Website: www.sajc.org			
	<b>DOI:</b> 10.4103/2278-330X.119901			

Table 1: Leading cancers and the prevalence in last 5 years in males

Cancer type	Prevalence in last 5 years (%)
Lung cancer	13.1
Lip and oral cavity cancer	11.9
Other pharynx	8.2
Colo-rectal cancer	6.5
Stomach cancer	4.7
Esophageal cancer	4.1
Non-Hodgkin lymphoma	4.7
Hodgkin lymphoma	2.2
Bladder cancer	3.4
Prostate cancer	2.3
Liver cancer	1.5
Leukemia	0.6

uteri cancer and breast cancer are most prevalent. Other cancer types which affect women are mouth and oropharynx cancer, lung cancer, and esophagus cancer. [1] The prevalence rates of the leading cancers in both males and females are presented in Tables 1 and 2.<sup>[3]</sup>

#### Causes of increased cancer prevalence Tobacco

Tobacco smoke contains approximately 4000 chemicals, of which at least 438 can cause cancer. Tobacco is the single most important modifiable risk factor (30%) for cancer.

Table 2: Leading cancers and the prevalence in last 5 years in female

Cancer type	Prevalence in last 5 years (%)
Breast cancer	32.8
Cervical cancer	26.1
Lip and oral cavity cancer	6.5
Ovarian cancer	3.3
Colo-rectal cancer	2.7
Lung cancer	2.0
Esophageal cancer	1.9
Stomach cancer	1.8
Non-Hodgkin lymphoma	1.3
Hodgkin lymphoma	0.8
Liver cancer	0.6

Unfortunately, in Bangladesh, cigarette production has grown tremendously since 1980, and bidi production has grown even faster. A WHO study showed that 20 million people in Bangladesh use tobacco in some form, including five million women and 57,000 people die every year due to tobacco-related diseases. Smoking prevalence in Bangladesh is 41% among men aged 15 years and over. In women, it was 1.8% among those aged 15 years and over. [4]

#### Sexual and reproductive factors

Sexual and reproductive factors are associated with cancer of the uterine cervix and breast. Sexual behavior factors, like young age at first sexual activity, multiple sexual partners, and poor sexual hygiene, are associated with cancer of the uterine cervix. Human Papilloma Virus (HPV) has now been identified as the etiological agent responsible for cervical cancer. HPV prevalence increases with high-risk sexual behavior and poor sexual hygiene. Late age at marriage, nulliparity, and late menopause have been linked to breast cancer.<sup>[3]</sup>

#### Diet

Foods which are responsible for cancers of oral cavity, pharynx, larynx, esophagus, liver, and breast include red meat (cow, goat), sugar, artificial sweetener, tea, fried food, dried fish, preserved foods, food adulteration and soft drinks. Changing dietary patterns will lead to increased contribution of diet in cancer causation in Bangladesh. [4]

#### Obesity

#### Physical inactivity

#### Cancer-causing viral and bacterial infection

Human Papilloma virus, Hepatitis B and Hepatitis C virus, Epstein-Barr virus, Schistosoma haematobium, *Helicobacter Pylori*.

# **Basic facilities available in various parts** of the country

#### Setting 1: Only basic care facilities

Only basic care and palliative oral treatment can be given in ASHIC Foundation. There are no oncology trained personnel available at the center and no specialized diagnostic facilities like histopathology, flow cytometry are available.

#### Setting 2: Regular cancer treatment facilities

According to International Atomic Energy Agency (IAEA),

# Various common oncology drugs available and not available

Anastrozole Bevacizumab Bleomycin Cabazitaxel Carboplatin Capecitabine Cyclophosphamide Dacarbazine Doxorubicin Hydrochloride Liposome Epirubicin Hydrochloride Etoposide Phosphate Etoposide Phosphate Etoposide Phosphate Everolimus Filgrastim Filgrastim Filgrastim Filgrastim Filgrastim Gemeitabine Ansiraterom Acetate Ado-Trastuzumab Emtansine Aldesleukin Ado-Trastuzumab Emtansine Aldesleukin Ado-Trastuzumab Emtansine Aldesleukin Aldesleukin Aminolevulinic Acid Aminolevalinic Acid Aminolevulinic Acid Aminolevalinic Acid Am
Bevacizumab Bleomycin Aldesleukin Cabazitaxel Alemtuzumab Carboplatin Capoplatin Capecitabine Cisplatin Cyclophosphamide Dacarbazine Dacarbazine Dacarbazine Docataxel Doxorubicin Hydrochloride Diposome Epirubicin Hydrochloride Etoposide Etoposide Phosphate Everolimus Filgrastim Fludarabine Phosphate Fluorouracil Gefitinib Gemcitabine Gemcitabine Devaradianib Decitabine Degarelix HPV Bivalent Vaccine, Recombinant Ifosfamide Imatinib Incaradianib Liposadianib Decrazovane Hydrochloride Itromotoracil Denosumab Imatinib Decrazovane Hydrochloride Itromotopag Olamine Eltrombopag Olamine Enzalutamide
Bleomycin Cabazitaxel Alemtuzumab Carboplatin Chlorambucil Capecitabine Cisplatin Cyclophosphamide Dacarbazine Dacarbazine Dacarbolicin Daunorubicin Hydrochloride Doxorubicin Hydrochloride Epirubicin Hydrochloride Etoposide Etoposide Etoposide Etoposide Everolimus Filgrastim Fludarabine Fludarabine Fludarabine Fluorouracil Gefitinib Gemcitabine Gemcitabine Hydrochloride Inatinib Decrazoxane Hydrochloride Fluorouracil Cyclophosphamide Axitinib Asparaginase Erwinia chrysanthemi Axacitidine Bendamustine Hydrochloride Bexarotene Bendamustine Hydrochloride Bexarotene Booxetavel Bortezomib Besvarotene Booxetavel Bortezomib Besvarotene Bortezomib Besvarotene Cabozantinib Geactinib Caffilzomib Carfilzomib Catfilzomib Cottarabine Cytarabine Cytarabine Cytarabine Cytarabine Fluorouracil Dasatinib Gefitinib Decitabine Degarelix HPV Bivalent Vaccine, Recombinant Ifosfamide Imatinib Dexrazoxane Hydrochloride Irinotecan Hydrochloride Eltrombopag Olamine Enzalutamide
Cabazitaxel Carboplatin Carboplatin Chlorambucil Capecitabine Cisplatin Cyclophosphamide Dacarbazine Dactinomycin Daunorubicin Hydrochloride Doxorubicin Hydrochloride Liposome Epirubicin Hydrochloride Etoposide Etoposide Phosphate Everolimus Filgrastim Fludarabine Phosphate Fludarabine Phosphate Fluorouracil Gefitinib Gemcitabine Gemcitabine Hydrochloride Cabosumab Hydrochloride Dosardinib Cytarabine Cytarabine Cytarabine Gemcitabine Gemcitabine Hydrochloride Liposomab Liposomal Fluorouracil Cytarabine Cytarabine Cytarabine Cytarabine Cytarabine Cytarabine Fludarabine Phosphate Fluorouracil Cefitinib Decitabine Decitabine Decitabine Decitabine Decitabine Decitabine Denosumab Imatinib Dexrazoxane Hydrochloride Eltrombopag Olamine Lapatinib Enzalutamide
Carboplatin Chlorambucil Capecitabine Cisplatin Cyclophosphamide Dacarbazine Dactinomycin Daunorubicin Hydrochloride Doxorubicin Hydrochloride Liposome Epirubicin Hydrochloride Etoposide Etoposide Phosphate Everolimus Filgrastim Fludarabine Pludarabine Fludarabine Fludarabine Fludarabine Gemcitabine Gemcitabine Hydrochloride Dexarazoxane Hydrochloride Etoposumab Fluorouracil Gefitinib Gemcitabine Hydrochloride Carposumab Cytarabine Fluorouracil Cefitinib Cemcitabine Decitabine Decitabine Decitabine Cytarabine Cy
Chlorambucil Capecitabine Cisplatin Cisplatin Cyclophosphamide Dacarbazine Dactinomycin Daunorubicin Hydrochloride Docetaxel Doxorubicin Hydrochloride Doxorubicin Hydrochloride Diposome Epirubicin Hydrochloride Etoposide Etoposide Etoposide Phosphate Everolimus Filgrastim Fludarabine Phosphate Fluorouracil Gefftinib Gemcitabine Hydrochloride Fluorouracil Geffizinib Gemcitabine Hydrochloride Fluorouracil Geffizinib Gemcitabine Imatinib Lapatinib Lapatinib Lapatinib Enzalutamide Lapatinib Arsenic Trioxide Arsenic Trioxide Asparaginase Erwinia chrysanthe Erwinia Asparaginase Erwinia chrysanthe Axitinib Asparaginase Erwinia chrysanthem  Axitinib Asparaginase Erwinia chrysanthem  Asparaginase Erwinia chrysanthem  Axitinib Asparaginase Erwinia chrysanthem  Axitinib Asparaginase Erwinia Chrysanthem  Floatunib Bexarotene  Bortezomib  Bexarotene Bexarotene  Bexarotene  Bexarotene  Bexarotene  Bexarotene  Bexarotene  Bexarotene  Bexarotene  Bexarotene  Bexarotene  Bexarotene  Cabozantinib-S-Malate  Caffilzomib Cabozantinib-S-Malat
Capecitabine Cisplatin Cisplatin Cyclophosphamide Dacarbazine Dactinomycin Daunorubicin Hydrochloride Docorubicin Hydrochloride Doxorubicin Hydrochloride Doxorubicin Hydrochloride Doxorubicin Hydrochloride Diposome Epirubicin Hydrochloride Etoposide Etoposide Etoposide Phosphate Everolimus Filgrastim Fludarabine Phosphate Fluorouracil Gefftinib Gemcitabine HPV Bivalent Vaccine, Recombinant Ifosfamide Imatinib Lapatinib Cyclophosphamide Arsenic Trioxide Axsenic Trioxide Axitinib  Bendamustine Hydrochloride Cabozantinib Postrazonib Brentuximab Vedotin  Cabozantinib-S-Malate Carfilzomib Cabozantinib-S-Malate Carfilzomib Cabozantinib-S-Malate Carfilzomib Crarfilzomib Cabozantinib-S-Malate Carfilzomib Cabozantinib-S-Malate Carfilzomib Crarfilzomib Cabozantinib-S-Malate Carfilzomib Cabozantinib Cabozantinib Cabozantinib Cabozantinib-S-Malate Cabozantinib Cabo
Cisplatin Asparaginase Erwinia chrysanthemi  Cyclophosphamide Axitinib  Dacarbazine Azacitidine  Dactinomycin Bendamustine Hydrochloride  Docetaxel Bortezomib  Doxorubicin Hydrochloride Besarotene  Doxorubicin Hydrochloride Bosutinib  Doxorubicin Hydrochloride Brentuximab Vedotin  Liposome  Epirubicin Hydrochloride Cabozantinib-S-Malate  Erlotinib Hydrochloride Carfilzomib  Etoposide Cetuximab  Etoposide Phosphate Clofarabine  Everolimus Crizotinib  Filgrastim Cytarabine  Fludarabine Phosphate Cytarabine, Liposomal  Fluorouracil Dasatinib  Gefitinib Decitabine  Gemcitabine Degarelix  HPV Bivalent Vaccine,  Recombinant  Ifosfamide Denosumab  Imatinib Dexrazoxane Hydrochloride  Irinotecan Hydrochloride Eltrombopag Olamine  Lapatinib  Enzalutamide
Cyclophosphamide Axitinib  Dacarbazine Azacitidine  Dactinomycin Bendamustine Hydrochloride  Docetaxel Bortezomib  Doxorubicin Hydrochloride Brentuximab Vedotin  Liposome Epirubicin Hydrochloride Etoposide Phosphate Everolimus Crizotinib  Filgrastim Cytarabine  Fludarabine Phosphate Fluorouracil Dasatinib  Gefitinib Decitabine  Gemcitabine  HPV Bivalent Vaccine, Recombinant  Ifosfamide Imatinib  Lapatinib Azacitidine  Bendamustine Hydrochloride Bendamustine Hydrochloride Bendamustine Hydrochloride Bendamustine Hydrochloride Bexarotene Boxutinib Bexarotene Cabocatinib Cabocatin
Cyclophosphamide Dacarbazine Dactinomycin Dactinomycin Daunorubicin Hydrochloride Docetaxel Doxorubicin Hydrochloride Doxorubicin Hydrochloride Doxorubicin Hydrochloride Liposome Epirubicin Hydrochloride Etoposide Etoposide Phosphate Everolimus Filgrastim Fludarabine Phosphate Fluorouracil Gefitinib Gemcitabine HPV Bivalent Vaccine, Recombinant Ifosfamide Imatinib Lapatinib Dacatitinib Dacatitinib Bendamustine Hydrochloride Bexarotene Boxutinib Bexarotenee Cabocatinib
Dacarbazine Dactinomycin Dactinomycin Daunorubicin Hydrochloride Docetaxel Docetaxel Doxorubicin Hydrochloride Doxorubicin Hydrochloride Diposome Epirubicin Hydrochloride Erlotinib Hydrochloride Etoposide Etoposide Etoposide Phosphate Everolimus Filgrastim Fludarabine Phosphate Fluorouracil Gefitinib Gemcitabine HPV Bivalent Vaccine, Recombinant Ifosfamide Imatinib Lapatinib Dacatitidine Bexarotene Bortezomib Bexarotene Boxella Bexarotene Bexarotene Bexarotene Bexarotene Bexarotene Bexarotene Bexarotene Boxella Bexarotene Cabozantinib Cabozantinib-S-Malate Carfilzomib Cabozantinib Cabozantinib Cabozantinib Cabozantinib-S-Malate Carfilzomib Cabozantinib-S-Malate Carfilzomib Cabozantinib-S-Malate Carfilzomib Catoximab Vedotin  Catoximab Vedo
Dactinomycin Daunorubicin Hydrochloride Docetaxel Docorubicin Hydrochloride Doxorubicin Hydrochloride Doxorubicin Hydrochloride Liposome Epirubicin Hydrochloride Etoposide Etoposide Phosphate Everolimus Filgrastim Fludarabine Phosphate Fluorouracil Gefitinib Gemcitabine HPV Bivalent Vaccine, Recombinant Ifosfamide Imatinib Dacatinib Docutaxel Bortezomib Bexarotene Boxarotene Boxutinib Bexarotene Boxevalene Boxutinib Brentuximab Vedotin Cabozantinib-S-Malate Carfilzomib Carfilzomib Catuximab Cetuximab Clofarabine Crizotinib Cytarabine Cytarabine Cytarabine Cytarabine Liposomal Decitabine Degarelix Denosumab Imatinib Dexrazoxane Hydrochloride Eltrombopag Olamine Lapatinib Enzalutamide
Daunorubicin Hydrochloride Docetaxel Doxorubicin Hydrochloride Doxorubicin Hydrochloride Liposome Epirubicin Hydrochloride Etoposide Etoposide Etoposide Phosphate Everolimus Filgrastim Fludarabine Phosphate Fluorouracil Gefitinib Gemcitabine HPV Bivalent Vaccine, Recombinant Ifosfamide Imatinib Loxorubicin Hydrochloride Espectation Brentuximab Capatinib Cabozantinib-S-Malate Carfilzomib Catrilzomib Catrilzomib Catrilzomib Catrilzomib Catrilamib Catrilamib Catrilamib Catrilamib Cytarabine Cytarabine Cytarabine Cytarabine Cytarabine Cytarabine Degarelix Denoileukin Diftitox Recombinant Ifosfamide Imatinib Dexrazoxane Hydrochloride Itrombopag Olamine Lapatinib Enzalutamide
Docetaxel Doxorubicin Hydrochloride Doxorubicin Hydrochloride Liposome Epirubicin Hydrochloride Etoposide Etoposide Etoposide Phosphate Everolimus Filgrastim Fludarabine Phosphate Fluorouracil Gefitinib Gemcitabine HPV Bivalent Vaccine, Recombinant Ifosfamide Imatinib Docetaxel Bortezomib Bosutinib Bosutinib Brentuximab Vedotin Cabozantinib-S-Malate Carfilzomib Cytarabine Cytarabine Cytarabine Cytarabine Liposomal Decitabine Degarelix Denoileukin Diftitox Recombinant Ifosfamide Denosumab Imatinib Dexrazoxane Hydrochloride Eltrombopag Olamine Lapatinib Enzalutamide
Doxorubicin Hydrochloride Doxorubicin Hydrochloride Liposome Epirubicin Hydrochloride Erlotinib Hydrochloride Etoposide Etoposide Phosphate Everolimus Filgrastim Fludarabine Phosphate Fluorouracil Gefitinib Gemcitabine HPV Bivalent Vaccine, Recombinant Ifosfamide Imatinib Lapatinib Doxorubicin Hydrochloride Eabosutinib Brentuximab Vedotin Cabozantinib Catfilzomib
Doxorubicin Hydrochloride Liposome  Epirubicin Hydrochloride Erlotinib Hydrochloride Etoposide Etoposide Phosphate Everolimus Filgrastim Fludarabine Phosphate Fluorouracil Gefitinib Gemcitabine HPV Bivalent Vaccine, Recombinant Ifosfamide Imatinib Inotecan Hydrochloride Lapatinib Epirubicin Hydrochloride Ecaposide Catologantinib-S-Malate Carfilzomib Cetuximab Cetuximab Clofarabine Cytarabine Cytarabine Cytarabine Cytarabine, Liposomal Dasatinib Decitabine Degarelix Denosumab Imatinib Denosumab Imatinib Denosumab Inatinib Enzalutamide
Liposome Epirubicin Hydrochloride Erlotinib Hydrochloride Etoposide Etoposide Cetuximab Etoposide Phosphate Everolimus Filgrastim Fludarabine Phosphate Fludarabine Phosphate Fluorouracil Gefitinib Gemcitabine HPV Bivalent Vaccine, Recombinant Ifosfamide Imatinib Lapatinib Captinib Captinib Cytarabine Cytarabine Cytarabine, Liposomal Dasatinib Decitabine Degarelix Denosumab Imatinib Denosumab Imatinib Dexrazoxane Hydrochloride Eltrombopag Olamine Lapatinib Enzalutamide
Epirubicin Hydrochloride Erlotinib Hydrochloride Etoposide Etoposide Phosphate Everolimus Filgrastim Fludarabine Phosphate Fluorouracil Gefitinib Gemcitabine HPV Bivalent Vaccine, Recombinant Ifosfamide Imatinib Lapatinib Epirubicin Hydrochloride Lapatinib Carfilzomib Cetuximab Clofarabine Cytarabine Cytarabine Cytarabine, Liposomal Dasatinib Decitabine Degarelix Denosumab Imatinib Denosumab Eltrombopag Olamine Enzalutamide
Erlotinib Hydrochloride Etoposide Etoposide Phosphate Everolimus Filgrastim Fludarabine Phosphate Fluorouracil Gefitinib Gemcitabine HPV Bivalent Vaccine, Recombinant Ifosfamide Imatinib Lapatinib Etoposide Phosphate Clofarabine Cytarabine Cytarabine, Liposomal Dasatinib Decitabine Degarelix Denileukin Diftitox Eltrombopag Olamine Lapatinib Enzalutamide
Etoposide Cetuximab  Etoposide Phosphate Clofarabine  Everolimus Crizotinib  Filgrastim Cytarabine  Fludarabine Phosphate Cytarabine, Liposomal  Fluorouracil Dasatinib  Gefitinib Decitabine  Gemcitabine Degarelix  HPV Bivalent Vaccine, Recombinant  Ifosfamide Denosumab  Imatinib Dexrazoxane Hydrochloride  Irinotecan Hydrochloride  Lapatinib Enzalutamide
Etoposide Phosphate  Everolimus  Filgrastim  Cytarabine  Fludarabine Phosphate  Fluorouracil  Gefitinib  Gemcitabine  HPV Bivalent Vaccine,  Recombinant  Ifosfamide  Imatinib  Dexrazoxane Hydrochloride  Lapatinib  Clofarabine  Cytarabine  Cytarabine, Liposomal  Desitabine  Degarelix  Denoileukin Diftitox  Retombinant  Eltrombopag Olamine  Enzalutamide
Everolimus Crizotinib Filgrastim Cytarabine Fludarabine Phosphate Cytarabine, Liposomal Fluorouracil Dasatinib Gefitinib Decitabine Gemcitabine Degarelix HPV Bivalent Vaccine, Recombinant Ifosfamide Denosumab Imatinib Dexrazoxane Hydrochloride Irinotecan Hydrochloride Lapatinib Enzalutamide
Filgrastim Cytarabine Fludarabine Phosphate Cytarabine, Liposomal Fluorouracil Dasatinib Gefitinib Decitabine Gemcitabine Degarelix HPV Bivalent Vaccine, Recombinant Ifosfamide Denosumab Imatinib Dexrazoxane Hydrochloride Irinotecan Hydrochloride Eltrombopag Olamine Lapatinib Enzalutamide
Fludarabine Phosphate  Fluorouracil  Gefitinib  Gemcitabine  HPV Bivalent Vaccine, Recombinant  Ifosfamide  Imatinib  Imatinib  Lapatinib  Cytarabine, Liposomal  Descitabine  Degarelix  Denileukin Diftitox  Denosumab  Denosumab  Eltrombopag Olamine  Enzalutamide
Fluorouracil Dasatinib Gefitinib Decitabine Gemcitabine Degarelix HPV Bivalent Vaccine, Recombinant Ifosfamide Denosumab Imatinib Dexrazoxane Hydrochloride Irinotecan Hydrochloride Eltrombopag Olamine Lapatinib Enzalutamide
Gefitinib Decitabine Gemcitabine Degarelix HPV Bivalent Vaccine, Recombinant Ifosfamide Denosumab Imatinib Dexrazoxane Hydrochloride Irinotecan Hydrochloride Eltrombopag Olamine Lapatinib Enzalutamide
Gemcitabine Degarelix HPV Bivalent Vaccine, Recombinant Ifosfamide Denosumab Imatinib Dexrazoxane Hydrochloride Irinotecan Hydrochloride Eltrombopag Olamine Lapatinib Enzalutamide
HPV Bivalent Vaccine, Recombinant  Ifosfamide Denosumab Imatinib Dexrazoxane Hydrochloride Irinotecan Hydrochloride Eltrombopag Olamine Lapatinib Enzalutamide
Recombinant Ifosfamide Denosumab Imatinib Dexrazoxane Hydrochloride Irinotecan Hydrochloride Eltrombopag Olamine Lapatinib Enzalutamide
IfosfamideDenosumabImatinibDexrazoxane HydrochlorideIrinotecan HydrochlorideEltrombopag OlamineLapatinibEnzalutamide
ImatinibDexrazoxane HydrochlorideIrinotecan HydrochlorideEltrombopag OlamineLapatinibEnzalutamide
Irinotecan Hydrochloride Eltrombopag Olamine Lapatinib Enzalutamide
Lapatinib Enzalutamide
Lapatinio Ditosylate Eriounii Wesylate
Lenograstim Exemestane
Letrozole Fulvestrant
Leucovorin Calcium Gemtuzumab Ozogamicin
Leuprolide Acetate Glucarpidase
Mesna HPV Quadrivalent Vaccine,
Recombinant
Methotrexate Ibritumomab Tiuxetan
Mitomycin C Imiquimod
Oxaliplatin Ipilimumab
Paclitaxel Ixabepilone
Pegfilgrastim Lenalidomide
Prednisone Liposomal Cytarabine
Procarbazine Hydrochloride Lomustine
Rituximab Mechlorethamine Hydrochloride
Sorafenib Tosylate Nelarabine
Sunitinib Malate Nilotinib

cont...

2 teletherapy machines and 1 brachytherapy machine are needed for 1 million population. According to this estimation Dhaka city alone needs 20 and the entire

Cont				
Available drug	Non-available drug			
Talc	Ofatumumab			
Tamoxifen Citrate	Omacetaxine Mepesuccinate			
Temozolomide	Paclitaxel Albumin-stabilized			
	Nanoparticle Formulation			
Thalidomide	Palifermin			
Trastuzumab	Palonosetron Hydrochloride			
Vinblastine Sulfate	Panitumumab			
Vincristine Sulfate	Pazopanib Hydrochloride			
Vinorelbine Tartrate	Pegaspargase			
Zoledronic Acid	Pemetrexed Disodium			
	Pertuzumab			
	Plerixafor			
	Pomalidomide			
	Ponatinib Hydrochloride			
	Pralatrexate			
	Raloxifene Hydrochloride			
	Rasburicase			
	Recombinant Interferon Alfa-2b			
	Regorafenib			
	Romidepsin			
	Romiplostim			
	Ruxolitinib Phosphate			
	Sclerosol Intrapleural Aerosol			
	(Talc)			
	Sipuleucel-T			
	Temsirolimus			
	Topotecan Hydrochloride			
	Toremifene			
	Tositumomab and I 131 Iodine			
	Tositumomab			
	Vandetanib			
	Vemurafenib			
	Vincristine Sulfate Liposome			
Vismodegib				
	Vorinostat			
	Ziv-Aflibercept			

# Various cancer programs, cancer initiatives and NGOs in Bangladesh [4]

National goals and objectives				
Goals	Objective			
To reduce the incidence of cancer through primary	Reduce the number of people who develop cancers due to tobacco use and second-hand smoke			
prevention	Reduce the number of people developing physical inactivity and obesity-related cancers			
	Reduce the number of people developing nutrition-related cancers			
	Reduce the number of people developing skin cancer due to UV radiation exposure Reduce the number of people developing infectious disease-related cancers			
	Reduce the number of people developing alcohol-related cancers			
	Reduce the number of people developing occupation-related cancers			
	4			

cont...

#### Cont...

Contin				
National goals and objectives				
Goals	Objective			
Ensure effective screening and early detection to reduce cancer incidence and mortality	At a national level, provide a strategic approach to cancer screening, and assessment and surveillance of those with familial risk, to ensure quality, acceptability, and effectiveness  Establish a process to assess the value of early detection of cancer other than that obtained through organized screening			
Ensure effective diagnosis and treatment of cancer	Provide optimal treatment for those with cancer			
to reduce morbidity and mortality	Develop defined standards for diagnosis, treatment, and care for those with cancer Ensure patient-centered and integrated care for those with cancer and their family			
Improve the quality of life for those with cancer, their family	Establish integrated programs of supportive care and rehabilitation with defined leadership			
and through support, rehabilitation, and palliative care	Ensure all people with cancer and their families are able to access the appropriate resources for support and rehabilitation that they need			
	Ensure all survivors of adult, childhood and adolescent cancer receive timely and ongoing support and rehabilitation, including early identification of, and intervention in, late effects			
	Ensure that those with cancer and their family have access to high-quality information treatment and care, including complementary and alternative medicine			
	Ensure optimal independence and function for those with cancer through systematic assessment and appropriate multidisciplinary intervention for their social and vocational needs			
	Continue to improve access to essential palliative care services that provide appropriate symptom relief and emotional, spiritual, cultural, and social support for those with cancer and their family			
	Ensure that integrated and comprehensive service is provided to all those with cancer who require palliative care and their family			

country needs around 300 Teletherapy (radiotherapy) machines respectively.

However, in Bangladesh there are 17 radiotherapy centers in public and private sector; only one is situated in a rural area. There are only 15 Linear Accelerators installed in the country with two installed in a rural area. 12 Cobalt- 60 machines and 12 brachytherapy machines are installed in Bangladesh [Table 3].

Bed capacity is around 500 beds all over the country which is insufficient for the current and future needs. [4] Among these, 64 beds are for day care and remaining are in indoor facility [Table 4].

Oncologist available: There are 150 qualified oncologists. Regular cancer treatment can be made available to patients in:

#### Hospital

National Institute of Cancer Research and Hospital, Dhaka

Khwaja Yunus Ali Medical College Hospital (Rural Centre)

Dhaka Medical College Hospital

Oncology Department BSMMU

Chittagong Medical College Hospital

Mymensingh Medical College Hospital

MAG Osmani Medical College Hospital, Sylhet

Sher-e-Bangla Medical College Hospital, Barisal

Rajshahi Medical College Hospital

Rangpur Medical College Hospital

Khulna Medical College Hospital

Shaheed Ziaur Rahman Medical College and Hospital, Bogra

Delta Oncology Center, Dhaka

Ahsania Mission Cancer Hospital, Dhaka

Square Hospital, Dhaka

United Hospital, Dhaka

Bangladesh Cancer Hospital and Welfare Home

North East Medical College Hospital, Sylhet

Enam Medical College Hospital, Savar

#### **Setting 3**

## Tertiary care centers, with research facilities are available in

- Bangabandhu Sheikh Mujib Medical University
- National Institute of Cancer Research and Hospital (NICRH)
- Khwaja Yunus Ali Medical College and Hospital- KYAMC Cancer Center
- Dhaka Medical College Hospital
- Sir Salimullah Medical College Hospital
- Sher-E-Bangla Medical College Hospital, Barisal
- Chittagong Medical College Hospital
- Mymensingh Medical College Hospital
- MAG Osmani Medical College Hospital, Sylhet
- Rajshahi Medical College Hospital
- Rangpur Medical College Hospital

Transplant facility: The only bone marrow transplant facility is available in Dhaka Medical College.

#### **Cancer programs**

- Breast Cancer Identifying and Treating Project; Amader Gram an ICT4D initiative of Bangladesh.
- The Government of Bangladesh, with support from UNFPA, has taken initiatives to develop a cervical and breast cancer screening program in Bangladesh.
- International Childhood Cancer Forum: Exploration and setting priorities for an unmet need in Bangladesh.
- The Bangladesh Women Chamber of Commerce and Industry has committed to raise the awareness of cervical cancer in every woman and every child.
- CANSUP, an NGO in Chittagong, is working on breast self-examination and cervical cancer screening with technical assistance from WHO.
- Gonoshasthaya Kendra is heading towards establishing

- a cancer hospital for the poor. The Government has already acquired the land, and Gonoshasthaya Kendra has started to mobilize resources and are requesting the philanthropists and donors to come forward in establishing the cancer hospital for the poor adjacent to Savar campus.
- ASHIC Foundation for childhood cancer improves the quality of life for children living with cancer in Bangladesh by providing hope, physical and emotional support, and raising public awareness for early detection, improved treatment, and social acceptance.
- Identifying and Treating Women with Advanced Breast Cancer in Bangladesh by Amader Gram.

#### NGOs working on cancer

ICDDRB, Ahsania Mission cancer Hospital, Bangladesh Cancer Society, AK Khan Healthcare Trust, Oncology Foundation, Oncology club, ASHIC Foundation, Amader Gram, Center for Cancer Prevention and Research, Cancer Support Society (CANSUP), BRAC, Gonoshasthaya Kendra.

# The number of patients annually treated at Khwaja Yunus Ali Medical College and Hospital (KYAMC Cancer Center):

Year 2012Radiation therapy patientsChemotherapyTeletherapyBrachytherapypatients20946002507

# Separate facilities of pediatric oncology in Banglasesh:

There are 16 pediatric oncologists in Bangladesh.<sup>[5]</sup>

Separate facilities for pediatric oncology are available in:

- Bangabandhu Sheikh Mujib Medical University
- National Institute of Cancer Research and Hospital (NICRH)
- Delta Oncology Center, Dhaka
- Square Hospital, Dhaka
- Dhaka Shishu Hospital
- Dhaka Medical College Hospital
- Sir Salimullah Medical College Hospital
- Sher-E-Bangla Medical College Hospital, Barisal
- Chittagong Medical College Hospital
- Mymensingh Medical College Hospital
- MAG Osmani Medical College Hospital, Sylhet
- Rajshahi Medical College Hospital
- Rangpur Medical College Hospital

# Problems being faced in the treatment of cancer patients in Bangladesh

- Financial problem
- Late diagnosis
- Poor radiotherapy facilities

<sup>\*</sup>Most of the public medical college hospitals do not have dedicated beds for cancer patients.<sup>[4]</sup>

Table 3: Radiotherapy facilities available in Bangladesh<sup>[4]</sup>

Hospital	Linear Accelerator	Co60 Teletherapy	Deep X-ray	Brachytherapy	Simulator	Treatment planning system
National Institute of Cancer Research and Hospital, Dhaka	3	2	0	3 Ir192/Co60/	1	2
				Cs137		
Khwaja Yunus Ali Medical College Hospital	2	0	0	1 Ir192	2	2
Dhaka Medical College Hospital	1	2 (non-functional)	2	1 (non-functional)	1	1
Oncology Department BSMMU	1 (in process)	0	0	1+1 (in process)	1 (in process)	1 (in process)
Chittagong Medical College Hospital	0	1	1	0	0	0
Sher-e-Bangla Medical College Hospital, Barisal	0	1	0	0	0	0
Mymensingh Medical College Hospital	0	1	0	0	0	0
MAG Osmani Medical College Hospital, Sylhet	0	1	0	0	0	0
Rajshahi Medical College Hospital	0	1	0	0	0	0
Rangpur Medical College Hospital	0	1	0	0	0	0
Delta Oncology Center, Dhaka	1	2	0	1	2	1
Ahsania Mission Cancer Hospital, Dhaka	1 (in process)	0	0	1 (in process)	1 (in process)	1 (in process)
Square Hospital, Dhaka	1	0	0	0	1	1
United Hospital, Dhaka	1	0	0	1	1	1
Khulna Medical College	1 (in process)	0	0	0	1 (in process)	1 (in process)
Shaheed Ziaur Rahman Medical College and Hospital, Bogra	1	0	0	0	1	1
Enam Medical College Hospital, Savar	1 (in process)	0	0	1 (in process)	1 (in process)	1 (in process)
North East Medical College Hospital, Sylhet	1 (in process)	0	0	1 (in process)	1 (in process)	1 (in process)
Total	15	12	3	12	14	14

Oncosurgery=Oncosurgery is available in all cancer hospitals

Table 4: Hospital beds attached to oncology/radiotherapy departments<sup>[4]</sup>

Name of the hospital	Day care		Indoor		Total
	M	F	M	F	
National Institute of Cancer Research and Hospital	8	8	25	25	66
Khwaja Yunus Ali Medical College and Hospital (Rural Centre)	5	5	24	24	58
BSMMU Oncology Department	5	5	5	5	20
Pediatric Hemato-Oncology Unit, Pediatric Deptt., BSMMU	0	0	14	14	28
Uro -Oncology Unit, Urology Deptt., BSMMU	-	-	9	9	18
Gyne-Oncology Unit, Gyne and Obstetrics Deptt., BSMMU	-	-	-	11	11
Dhaka Medical College Hospital	0	0	11	13	24
Rajshahi Medical College Hospital	0	0	6	4	10
Mymensingh Medical College Hospital	0	0	10	4	14
Sylhet Medical College Hospital	0	0	8	4	12
Chittagong Medical College Hospital	0	0	8	4	12
Delta Oncology Center	5	3	40	40	88
Ahsania Mission Cancer Hospital	5	5	16	16	42
Bangladesh Cancer Society Hospital	0	0	10	10	20
Cancer Foundation Hospital	5	5	5	5	20
Enam Medical College Hospital, Savar			10	10	20
North East Medical College Hospital, Sylhet			10	10	20
Total					465

\*Most of the public medical college hospitals do not have dedicated beds for cancer patients<sup>[4]</sup>

- Unavailability of a complete cancer-specialized hospital
- Poor funding from government for cancer
- Lack of NGOs to tackle the problem

- Lack of cancer registries
- Low levels of awareness.

## Priorities to improve the oncology scenario in Bangladesh

To improve the oncology scenario, at first goal set-up is very important as described under National Goals and Objectives. [4]

To meet these goals, specific objectives have been established, which are given below:

- To create awareness about tobacco-related cancer and harmful effects through anti-tobacco action programs involving student volunteers, scouts, inter-sectoral personnel, medical personnel, and people at large.
- To attain Early Clinical Diagnosis (ECD) of oral, cervical, breast, and other cancers through circulation of warning signs/symptoms, screening and motivation, and expand laboratory diagnostic support through medical university/college hospitals and district level early cancer detection program and early detection
- To extend the therapy by introducing minimal therapy for early cancer at the periphery and comprehensive multi-disciplinary protocol-based therapy with early detection in oncology/radiotherapy departments of medical colleges and palliative care at the district level.
- To widen the coverage and reach of palliative care by providing human resource and supplying necessary drugs and equipments to district level, collaborating with NGOs for home care service.
- To improve the quality of life for cancer patients and their family through support, rehabilitation, and palliative care.
- To develop the effective delivery of services across the continuum of cancer control through effective planning, co-ordination, and integration of resources and activity, monitoring, and evaluation.
- To generate essential evidence for effective cancer control through research and surveillance.

#### Conclusion

Bangladesh is suffering from the double burden of both

communicable and non-communicable diseases. So, improvement of cancer scenario overnight is not very easy for a country like Bangladesh. It is very important to know the cancer burden of Bangladesh. So, it is needed to find out disability-adjusted life year (DALY), Years of Life Lost (YLL) due to premature mortality in the population and the Years Lost due to Disability (YLD) and overall health impact assessment (HIA) for cancer. Policy makers may become interested in these issues when they understand that cancer causes a huge health impact and economic loss for Bangladesh.

### **Acknowledgment**

World Health Organization, Country Office-Bangladesh. Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh. National Institute of Cancer Research and Hospital, Dhaka, Bangladesh. Khwaja Yunus Ali Medical College and Hospital.

#### References

- Uddin AK, Khan ZJ, Islam J, Mahmud AM. Cancer care scenario in Bangladesh. South Asian J Cancer 2013;2:102-4
- Noronha V, Tsomo U, Jamshed A, Hai MA, Wattegama S, Baral RP, et al. A fresh look at oncology facts on south central Asia and SAARC countries. South Asian J Cancer 2012; 1:1-4.
- Cancer Registry Report National Institute of Cancer Research and Hospital 2005-2007. Available from: http://whobangladesh. healthrepository.org/bitstream/123456789/282/1/Publication\_ Cancer\_Registry\_Report.pdf [Last accessed on 2013 May 03].
- National Cancer Control Strategy and Plan of Action 2009-2015. Directorate General of Health Services. Ministry of Health and Family Welfare, Bangladesh. Available from: http://www.ban.searo.who. int/LinkFiles/Publication Cancer Strategy.pdf. [Last accessed on
- Islam A, Eden T. Brief report on pediatric oncology in Bangladesh. South Asian J Cancer 2013;2:105-6.

How to cite this article: Hussain SM. Comprehensive update on cancer scenario of Bangladesh. South Asian J Cancer 2013;2:279-84. Source of Support: Nil. Conflict of Interest: None declared.

#### News

**Indian Cancer Congress 2013** 21st to 24th November 2013 Kempinsky Ambience Hotel, New Delhi, India alongwith

35th Annual Conference of Association of Radiation Oncologists of India (AROI) 27th Annual Conference of Indian Association of Surgical Oncology (IASO) 18th Conference of Indian Society of Medical & Pediatric Oncology (ISMPO) 15th Biennial Conference of Indian Society of Oncology (ISO) Oncology Forum and 25 other organizations